Mucins in ovarian cancer diagnosis and therapy
- PMID: 20034397
- PMCID: PMC2804676
- DOI: 10.1186/1757-2215-2-21
Mucins in ovarian cancer diagnosis and therapy
Abstract
Ovarian cancer is the most lethal gynecologic malignancy and the five-year survival rate is only 35% after diagnosis. Epithelial ovarian cancer is a highly metastatic disease characterized by widespread peritoneal dissemination and ascites. The death incidences from ovarian cancer could be significantly lowered by developing new methods for the early diagnosis and treatment of this fatal disease. Several potential markers have been identified recently. However, mucins are the most promising markers for ovarian cancer diagnosis. Mucins are large extracellular, heavily glycosylated proteins and their aberrant expression has been implicated in the pathogenesis of a variety of cancers, including ovarian cancer. This review will summarize known facts about the pathological and molecular characteristics of ovarian cancer, the current status of ovarian cancer markers, as well as general information about mucins, the putative role of mucins in the progression of ovarian cancer and their potential use for the early diagnosis and treatment of this disease.
Figures
Similar articles
-
Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.Lancet Oncol. 2008 Nov;9(11):1076-85. doi: 10.1016/S1470-2045(08)70277-8. Lancet Oncol. 2008. PMID: 19012856 Free PMC article. Review.
-
Mucin gene expression in ovarian cancers.Cancer Res. 1998 Dec 1;58(23):5546-50. Cancer Res. 1998. PMID: 9850092
-
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.Oncologist. 1996;1(5):326-330. Oncologist. 1996. PMID: 10388011
-
Circulating mucins as tumor markers in ovarian cancer (review).Anticancer Res. 1992 May-Jun;12(3):709-17. Anticancer Res. 1992. PMID: 1622128 Review.
-
GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment.Redox Biol. 2019 Jul;25:101051. doi: 10.1016/j.redox.2018.11.009. Epub 2018 Nov 17. Redox Biol. 2019. PMID: 30509602 Free PMC article.
Cited by
-
Measuring the multifaceted roles of mucin-domain glycoproteins in cancer.Adv Cancer Res. 2023;157:83-121. doi: 10.1016/bs.acr.2022.09.001. Epub 2022 Oct 8. Adv Cancer Res. 2023. PMID: 36725114 Free PMC article. Review.
-
Molecular expression of adenosine receptors in OVCAR-3, Caov-4 and SKOV-3 human ovarian cancer cell lines.Res Pharm Sci. 2015 Jan-Feb;10(1):43-51. Res Pharm Sci. 2015. PMID: 26430456 Free PMC article.
-
The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.PLoS One. 2015 Jun 15;10(6):e0130197. doi: 10.1371/journal.pone.0130197. eCollection 2015. PLoS One. 2015. PMID: 26075384 Free PMC article.
-
Gene-expression signatures can distinguish gastric cancer grades and stages.PLoS One. 2011 Mar 18;6(3):e17819. doi: 10.1371/journal.pone.0017819. PLoS One. 2011. PMID: 21445269 Free PMC article.
-
Mucin-Targeted Antibodies for Ovarian Cancer.Semin Nucl Med. 2025 Jul 3:S0001-2998(25)00071-6. doi: 10.1053/j.semnuclmed.2025.06.007. Online ahead of print. Semin Nucl Med. 2025. PMID: 40615275 Review.
References
-
- Alexander-Sefre F, Menon U, Jacobs IJ. Ovarian cancer screening. Hosp Med. 2002;63:210–213. - PubMed
-
- Ozols RF. Update on the management of ovarian cancer. Cancer J. 2002;8(Suppl 1):S22–30. - PubMed
-
- Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol. 1998;25:281–304. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources